The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you
Taskus, Inc. (NASDAQ:TASK)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/taskus-inc-loss-submission-form?prid=25405&wire=1
Lead Plaintiff Deadline: April 25, 2022
Class Period: June 11, 2021 - January 19, 2022
Allegations against TASK include that: (1) TaskUs was experiencing severe financial strain and business challenges, particularly with its most important customer, Facebook; (2) the Content Security market was smaller than defendants represented and defendants' representations were based on outdated market data; (3) TaskUs improperly recognized revenue from certain key contracts; (4) defendants overstated the size of TaskUs' workforce as well as employee retention rates, and understated attrition rates; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
Cabaletta Bio, Inc. (NASDAQ:CABA)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=25405&wire=1
Lead Plaintiff Deadline: April 29, 2022
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Allegations against CABA include that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Meta Platforms, Inc. (NASDAQ:FB)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/meta-platforms-inc-loss-submission-form?prid=25405&wire=1
Lead Plaintiff Deadline: May 9, 2022
Class Period: March 2, 2021 - February 2, 2022
Allegations against FB include that: (1) Apple's iOS privacy changes were having a material impact on Meta's ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta's mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: